Aluminium Toxicity in Rats

Berlyne, G.M.; Ari, J. Ben; Knopf, E; Yagil, R.; Weinberger, Gerald; Danovitch, Gabriel M.

doi:10.1016/s0140-6736(72)90357-1

Cited by 176 publications

(54 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the use of Al(OH)3 in the prophylaxis of hyperphosphatemia has been questioned because of toxicity reported by Berlyne et al (509,510). The toxicity seen in uremic rats (5/6 nephrectomy) given subcutaneous (SC) injections or drinking water containing 10 g…”

Section: Toxicology Of Aluminum and Its Compoundsmentioning

confidence: 99%

“…The periorbital bleeding could not be independently reproduced by Thurston et al (344,345), and they suggested it was the result of a possible local infection. Failure to confirm the originally reported toxicity (509,510) suggested that elimination of AI(OH)3 from therapeutic use in the treatment of renal Environmental Health Perspectivesdisease was unwarranted, according to Bailey et al (341), Sherrard (343), and Thurston et al…”

Section: Toxicology Of Aluminum and Its Compoundsmentioning

confidence: 99%

“…Experimental animal work (478,509) shows that high doses of dietary Al impair growth, apparently through interference with phosphate metabolism. No impairment of growth occurs in experimental situations when hypophosphatemia is avoided (344 (48,342,345,346,510,717).…”

Section: Medicinal Uses Of Aluminummentioning

confidence: 99%

See 2 more Smart Citations

Aluminum in the Environment and Human Health

Sorenson¹,

Campbell²,

Tepper³

et al. 1974

Environmental Health Perspectives

View full text Add to dashboard Cite

The review of over 800 references on aluminum (Al) published since the mid-fifties covers the occurrence of Al in soil, air, water, plants and food products, as well as air and water pollution problems. In addition, the existing quality criteria, the biology and toxicology of Al, and the therapeutic and medical uses are presented. It is concluded that absorption and retention or accumulation of Al in humans occurs at lower levels of intake than had been assumed formerly. However, levels of 5 to 50 times the normal daily intake do not appear to interfere with other metabolic processes. The adverse effects of Al reported in the more recent years resulted from the inhalation or ingestion of Al in concentrations many times greater than the amounts present under normal circumstances. As in the past, there is still no need for .ncern by the public or producers of Al or its products concerning hazards to human health derived from well established and extensively used products.

show abstract

Section: Toxicology Of Aluminum and Its Compoundsmentioning

confidence: 99%

Section: Toxicology Of Aluminum and Its Compoundsmentioning

confidence: 99%

See 1 more Smart Citation

Aluminum in the Environment and Human Health

Sorenson¹,

Campbell²,

Tepper³

et al. 1974

Environmental Health Perspectives

View full text Add to dashboard Cite

show abstract

“…Thurston et al (1972), as a result of their studies on the effects of aluminium hydroxide in normal rats and rats with chronic renal failure, concluded that aluminium accumulated in bone, but that any 832 Bone aluminium and mineralisation mineralisation defect that occurred resulted from the accompanying hypophosphataemia and could be prevented by giving the animals a dietary supplement of phosphate. In their opinion, the symptoms of aluminum toxicity described by Berlyne et al (1972) are non-specific.…”

mentioning

confidence: 99%

Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation.

Ellis¹,

McCarthy²,

Herrington³

1979

J Clin Pathol

259

View full text Add to dashboard Cite

“…Traditionally, calcium or aluminum-based agents were initially used as phosphate binders to reduce serum phosphate levels rely on the actions of ionic bonds. But the abnormally elevated level of aluminum caused by a long-term administration can result in increased neurological, hematologic and skeletal toxicity [24][25][26][27]; otherwise, the hypercalcemia may lead to serious cardiovascular diseases and soft-tissue calcification [28][29][30]. Later on, Fosrenol® (lanthanum carbonate) was developed to replace calcium-based preparations [31,32].…”

Section: Introductionmentioning

confidence: 99%

Chitosan: A Desirable Candidate for Treating Hyperphosphatemia?

Zhang¹,

Meng²,

Zhang³

2016

JPP

View full text Add to dashboard Cite

Non-absorbed macromolecular binders as sequestrants for phosphate ions offer an effective approach to treat hyperphosphatemia in ESRD (end-stage renal disease) patients. RenaGel® has been an example with remarkable success of a polymer synthesized to prevent the absorption of dietary phosphate for ESRD patients. Electrostatic interaction is the primary driving force for complexation of phosphate-based anions with these amino groups in the polymer backbone. Chitosan is a deacetylation product of chitin, which is the structural element in the exoskeleton of crustaceans and cell walls of fungi. The amino groups in the backbone give the phosphate binding ability to chitosan. This article has demonstrated that chitosan exhibited a phosphate binding effect indeed. Thus, it has potential applications in environmental management and wastewater treatment, as well as treatment of hyperphosphatemia patients.

show abstract

Aluminium Toxicity in Rats

Cited by 176 publications

References 7 publications

Aluminum in the Environment and Human Health

Aluminum in the Environment and Human Health

Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation.

Chitosan: A Desirable Candidate for Treating Hyperphosphatemia?

Contact Info

Product

Resources

About